Biology. Technology. Human potential.
Longevity, neurotechnology, gene engineering and the public and private companies expanding human possibility. Follow the breakthroughs. Understand the evidence.
Free to read. Explore a sample Monitor: no sign-up. Paid plans from $49/month.
“SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results fo…”
22 public and 11 private companiesListed status and private ownership checked against SEC records
149 developments, each sourcedFrom 586 filings, offering notices and award records read
Sources checked: on scheduleLast full check Oct 29, 2026, 06:17 UTC
Explore by frontier
Latest
Company press release furnished with a Form 8-K filed on Oct 28, 2026.
Current report (Form 8-K) filed with the SEC on Oct 27, 2026; the quoted text is from Item 5.02.
Company press release furnished to the SEC with a Form 6-K report on Oct 26, 2026.
Company press release furnished with a Form 8-K filed on Oct 26, 2026.
Company press release furnished to the SEC with a Form 6-K report on Oct 19, 2026.
Current report (Form 8-K) filed with the SEC on Oct 19, 2026; the quoted text is from Item 5.02.
Research should distinguish, not blur
Every company record keeps ownership, commercial development and investment access apart, each with its own source and date. You can follow any company. We never show a buy button.
Neurotechnology & BCI · Deep transcranial magnetic stimulation
Neurotechnology & BCI · Implanted brain-computer interface
Coverage is not an offer to invest. Private ownership does not imply available shares.
The Sapien Frontier lens
The frontier attracts big claims. We separate what was reported, what the evidence supports, and what remains unknown, so curiosity never has to mean credulity.
What was reported
SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026.
What the evidence supports
ClearPoint Neuro published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Original tracker
Who is raising money at the human frontier, from the notices private companies file with the SEC and the federal grants on record. Amounts sold are not valuations.
| Company | Frontier | Amount sold | Filed | Investors | Exemption |
|---|---|---|---|---|---|
| Precision Neuroscience | Neurotechnology & BCI | $250.0M | Sep 28, 2026 | 46 | Rule 506(b) |
| Cambrian Bio | Longevity | $123.8M | Jul 15, 2026 | 80 | Rule 506(c) |
| Lifeward | Physical augmentation | $11.2M | Jul 8, 2026 | 5 | Rule 506(b) |
| Rejuvenate Bio | Longevity · Gene & cell engineering | $19.5M | Jun 18, 2026 | 35 | Rule 506(b) |
| Life Biosciences | Longevity | $31.0M | Apr 24, 2026 | 8 | Rule 506(b) |
| Longeveron | Longevity · Regeneration | $15.9M | Mar 25, 2026 | 7 | Rule 506(b) |
The Monitor
Neuralink and every brain-computer interface company, say. Or every longevity company’s raises.
Automatically, every day, from the SEC and USAspending.gov. Each claim is checked against its source.
Daily or weekly, with the source beside every item and what remains unknown. Quiet weeks say so.
Choose companies and frontiers; the sample shows the real records from the last 90 days. No sign-up.
The Frontier Brief
Important developments, useful context and the evidence behind the headlines. Free to read. Unsubscribe at any time.
